JAX Home

Edison T. Liu, M.D.

President, CEO

Conducts research focused on the functional genomics of breast cancer through an exploration of the entire genomic space.

The Jackson Laboratory Cancer Center

Visit The Liu Lab

About Edison T. Liu, M.D.

Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001-2011), and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he was in charge of the intramural clinical translational science programs.

From 1987 to 1996, Dr. Liu was a faculty member at the University of North Carolina at Chapel Hill, where he was the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer; the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health; chief of Medical Genetics; and the chair of the Correlative Science Committee of the national cooperative clinical trials group, CALGB. Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology and translational medicine.

Dr. Liu's own scientific research has focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering on a genomic scale the dynamics of gene regulation that modulate cancer biology. He has authored over 300 scientific papers and reviews, and co-authored two books. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. From 1982 to 1987 he was at the University of California, San Francisco, at the G.W. Hooper Foundation.

Grants, honors and accomplishments

2014 April - 2014 Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research (from the Human Genome Organization)

2013 January - Elected, Fellow of the Connecticut Academy of Sciences and Engineering

2010 October - Fellow of the Hastings Center (New York, Elected Membership)

2010-2013 - Re-elected - President, Human Genome Organization (HUGO)

2008 - Elected, Foreign Associate Member, European Molecular Biology Organization (EMBO)

July 2007 - Awarded Doctor of Medical Sciences honoris causa, Queen’s University, Belfast September

June 2007-2010 - Elected – President, Human Genome Organization (HUGO)

September 2003 - Public Service Medal (National Day, 2003): for work in controlling SARS in Singapore (given by the Office of the President, Republic of Singapore)

April 2000 - Rosenthal Award, AACR: for the discovery that HER-2 status determines response to adjuvant chemotherapy with doxorubicin.

April 1999-2001 - Elected-Board of Directors, American Association for Cancer Research

October 1996 - 1996 Brinker International Award for Breast Cancer Research - Basic Research Award

July 1995 - American Society of Clinical Investigation (Elected Membership)

December 1991-November1996 - Leukemia Society Scholar

October 1990-1993 - Komen Foundation Award for Breast Cancer Research (funding fellow salary)

July 1990-June 1994 - Jefferson Pilot Award: University of North Carolina at Chapel Hill, Junior Faculty Award for Research Excellence

July 1985-1988 - Clinical Investigator Award, National Cancer Institute, K08- CA01036-02, Preceptor: Dr. J. Michael Bishop.

September 1983-1985 - Damon Runyan Cancer Fund Fellowship Preceptor: Dr. J. Michael Bishop (UCSF)

July-September 1974 - Ford Foundation Fellowship for Intensive Studies in Chinese, Stanford University

June 1973 - Phi Beta Kappa, Stanford University

June-September 1972 - National Science Foundation Fellowship in Chemistry 1972. To study the photoconversion of aziridines to ethylene for its agriculture applications. Preceptor: Dr. J. D. White

Selected Publications

Highlighted Abstract

Next-generation sequencing studies have revealed genome-wide structural variation patterns in cancer, such as chromothripsis and chromoplexy, that do not engage a single discernable driver mutation, and whose clinical relevance is unclear. We devised a robust genomic metric able to identify cancers with a chromotype called tandem duplicator phenotype (TDP) characterized by frequent and distributed tandem duplications (TDs). Enriched only in triple-negative breast cancer (TNBC) and in ovarian, endometrial, and liver cancers, TDP tumors conjointly exhibit tumor protein p53 (TP53) mutations, disruption of breast cancer 1 (BRCA1), and increased expression of DNA replication genes pointing at rereplication in a defective checkpoint environment as a plausible causal mechanism. The resultant TDs in TDP augment global oncogene expression and disrupt tumor suppressor genes. Importantly, the TDP strongly correlates with cisplatin sensitivity in both TNBC cell lines and primary patient-derived xenografts. We conclude that the TDP is a common cancer chromotype that coordinately alters oncogene/tumor suppressor expression with potential as a marker for chemotherapeutic response.

View full list of publications

Tech CornerJuly 17, 2019
Improved methods, expanded capabilities: Analyzing cells one at a time
Researchers are able to do many things today that were impossible five, three, even one year ago. Some of the new options are science-fiction-level impressive.
Press ReleaseJuly 15, 2019
Research team creates new research models for Snyder-Robinson Syndrome
Two new mouse models created to study neurological developments in Snyder-Robinson Syndrome to advance global understanding of this rare disease.
Search MagazineJune 18, 2019
Connected through Science
When Isabelle Chen, a senior at The Ethel Walker School in Simsbury, Conn., met Ann Bresnahan ‘69 during a science alumnae panel discussion at Bresnahan’s 50-year high school reunion, the two knew that they shared a passion for science.
Blog PostJune 05, 2019
Multigene panels for hereditary breast cancer risk
Genetic testing is becoming increasingly accessible for patients as the list of clinical indications and number of genes are growing, and the cost of testing is decreasing.

Research HighlightJuly 17, 2019
JAX postdoc Kira Young lands ASH Scholar Award
JAX postdoctoral associate Kira Young, Ph.D., has received the ASH Scholar Award from the American Society for Hematology to support her research studying “old blood.” Young is using the award to understand the different types of white blood cells that make up the immune system and how they change as we age.
- Aging
- Cancer
Search MagazineJuly 02, 2019
Who does what in a lab: scientist job titles explained
Ever wonder who does what in a research lab? We joined the Bolcun-Filas group for a day to learn about the scientists who work together on female fertility.
Tech CornerJune 17, 2019
The genome of Eve (the mouse)
C57BL/6—aka Black 6—is the most widely used mouse strain in research. Its reference genome was published in 2003 and has been carefully curated over the years since.
Featured ArticleJune 04, 2019
MCGI Advances clinical genomics education in Maine
Oncology practices in Maine will continue to have access to advanced educational curricula on genomic tumor testing in patient care through the Maine Cancer Genomics Initiative (MCGI), thanks to a gift from the Maine Cancer Foundation.
- Meet our donors
- Cancer